<doc:document xmlns:doc="http://www.elsevier.com/xml/document/schema" xmlns:dp="http://www.elsevier.com/xml/common/doc-properties/schema" xmlns:cps="http://www.elsevier.com/xml/common/consyn-properties/schema" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dct="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:oa="http://vtw.elsevier.com/data/ns/properties/OpenAccess-1/" xmlns:bam="http://vtw.elsevier.com/data/voc/ns/bam-vtw-1/" xmlns:cp="http://vtw.elsevier.com/data/ns/properties/Copyright-1/" xmlns:cja="http://www.elsevier.com/xml/cja/schema" xmlns:ja="http://www.elsevier.com/xml/ja/schema" xmlns:bk="http://www.elsevier.com/xml/bk/schema" xmlns:ce="http://www.elsevier.com/xml/common/schema" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:cals="http://www.elsevier.com/xml/common/cals/schema" xmlns:tb="http://www.elsevier.com/xml/common/table/schema" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/schema" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/schema" xmlns:xlink="http://www.w3.org/1999/xlink"><rdf:RDF><rdf:Description rdf:about="http://dx.doi.org/10.1016/j.phyplu.2022.100218"><dct:format>application/xml</dct:format><dct:title>Anti-diabetic potential of &#x2018;Saf&#x016b;f-i-Dhay&#x0101;b&#x012b;tus&#x2019; as standalone and as an adjuvant with glibenclamide in streptozotocin-induced diabetic rats</dct:title><dct:creator>Abu Nasir</dct:creator><dct:creator>Athar Parvez Ansari</dct:creator><dct:creator>Towseef Amin Rafeeqi</dct:creator><dct:creator>Pankaj Goswami</dct:creator><dct:creator>Abdul Wadud</dct:creator><dct:creator>Seema Akbar</dct:creator><dct:creator>Huzaifa Ansari</dct:creator><dct:subject><rdf:Bag><rdf:li>Diabetes mellitus</rdf:li><rdf:li>Saf&#x016b;f-i-Dhay&#x0101;b&#x012b;tus</rdf:li><rdf:li>Antidiabetic</rdf:li><rdf:li>Adjuvant therapy</rdf:li><rdf:li>Glibenclamide</rdf:li><rdf:li>Unani medicine</rdf:li></rdf:Bag></dct:subject><dct:description>Phytomedicine Plus 2 (2022). doi:10.1016/j.phyplu.2022.100218</dct:description><prism:aggregationType>journal</prism:aggregationType><prism:publicationName>Phytomedicine Plus</prism:publicationName><prism:copyright>&#169; 2022 The Author(s). Published by Elsevier B.V.</prism:copyright><dct:publisher>Elsevier B.V.</dct:publisher><prism:issn>2667-0313</prism:issn><prism:volume>2</prism:volume><prism:number>1</prism:number><prism:coverDisplayDate>February 2022</prism:coverDisplayDate><prism:doi>10.1016/j.phyplu.2022.100218</prism:doi><prism:url>http://dx.doi.org/10.1016/j.phyplu.2022.100218</prism:url><dct:identifier>doi:10.1016/j.phyplu.2022.100218</dct:identifier><bam:articleNumber>100218</bam:articleNumber><oa:openAccessInformation><oa:openAccessStatus xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">http://vtw.elsevier.com/data/voc/oa/OpenAccessStatus#Full</oa:openAccessStatus><oa:openAccessEffective xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">2022-01-09T06:42:59Z</oa:openAccessEffective><oa:sponsor xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><oa:sponsorType>http://vtw.elsevier.com/data/voc/oa/SponsorType#Author</oa:sponsorType></oa:sponsor><oa:userLicense xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">http://creativecommons.org/licenses/by-nc-nd/4.0/</oa:userLicense></oa:openAccessInformation><cp:licenseLine xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">This is an open access article under the CC BY-NC-ND license.</cp:licenseLine></rdf:Description></rdf:RDF><dp:document-properties><dp:aggregation-type>Journals</dp:aggregation-type><dp:version-number>S300.1</dp:version-number></dp:document-properties><ja:article docsubtype="fla" version="5.6" xml:lang="en"><ja:item-info><ja:jid>PHYPLU</ja:jid><ja:aid>100218</ja:aid><ce:article-number>100218</ce:article-number><ce:pii>S2667-0313(22)00004-5</ce:pii><ce:doi>10.1016/j.phyplu.2022.100218</ce:doi><ce:copyright type="other" year="2022">The Author(s)</ce:copyright></ja:item-info><ja:head><ce:title id="tte0002">Anti-diabetic potential of &#x2018;<ce:italic>Saf&#x016b;f-i-Dhay&#x0101;b&#x012b;tus</ce:italic>&#x2019; as standalone and as an adjuvant with glibenclamide in streptozotocin-induced diabetic rats</ce:title><ce:author-group id="aut0001"><ce:author id="au0001" author-id="S2667031322000045-110bef5d3e2d58ae2994b286c2f2cab8"><ce:given-name>Abu</ce:given-name><ce:surname>Nasir</ce:surname><ce:cross-ref refid="aff0001"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:author id="au0002" author-id="S2667031322000045-25a096893c7cc6d1615f52f040c6a340"><ce:given-name>Athar Parvez</ce:given-name><ce:surname>Ansari</ce:surname><ce:cross-ref refid="aff0001"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="cor0001"><ce:sup loc="post">&#x204e;</ce:sup></ce:cross-ref><ce:e-address id="ead0001" type="email" xlink:href="mailto:aatharparvez@gmail.com">aatharparvez@gmail.com</ce:e-address><ce:e-address id="url0001" type="url" xlink:href="https://orcid.org/0000-0002-5755-3525">https://orcid.org/0000-0002-5755-3525</ce:e-address></ce:author><ce:author id="au0003" author-id="S2667031322000045-7675233ce89036563949be3428d50058"><ce:given-name>Towseef Amin</ce:given-name><ce:surname>Rafeeqi</ce:surname><ce:cross-ref refid="aff0001"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:author id="au0004" author-id="S2667031322000045-d82593f43c9d5f779c985fbbb661a690"><ce:given-name>Pankaj</ce:given-name><ce:surname>Goswami</ce:surname><ce:cross-ref refid="aff0002"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author id="au0005" author-id="S2667031322000045-b865f0d8768f91e031a78f37dfef5b77"><ce:given-name>Abdul</ce:given-name><ce:surname>Wadud</ce:surname><ce:cross-ref refid="aff0003"><ce:sup loc="post">c</ce:sup></ce:cross-ref></ce:author><ce:author id="au0006" author-id="S2667031322000045-bacad66aa86b459817b00db646ecf926"><ce:given-name>Seema</ce:given-name><ce:surname>Akbar</ce:surname><ce:cross-ref refid="aff0001"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:author id="au0007" author-id="S2667031322000045-e855170dc1a544be42986f948f150746"><ce:given-name>Huzaifa</ce:given-name><ce:surname>Ansari</ce:surname><ce:cross-ref refid="aff0001"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="aff0001" affiliation-id="S2667031322000045-6c2848c322fa4446186fd594084e6646"><ce:label>a</ce:label><ce:textfn id="cetextfn0001">Regional Research Institute of Unani Medicine, Srinagar, Jammu &amp; Kashmir, CCRUM, Ministry of AYUSH, Govt. of India, India</ce:textfn><sa:affiliation><sa:organization>Regional Research Institute of Unani Medicine, Srinagar, Jammu &amp; Kashmir, CCRUM, Ministry of AYUSH, Govt. of India</sa:organization><sa:country>India</sa:country></sa:affiliation><ce:source-text id="staff0001">aRegional Research Institute of Unani Medicine, Srinagar, Jammu &amp; Kashmir, CCRUM, Ministry of AYUSH, Govt. of India, India</ce:source-text></ce:affiliation><ce:affiliation id="aff0002" affiliation-id="S2667031322000045-af20d1b67d8c05cbae68a5ac2732f9cf"><ce:label>b</ce:label><ce:textfn id="cetextfn0002">Division of Veterinary Pathology, Sher-e-Kashmir University of Agriculture Sciences and Technology of Jammu, R. S. Pura, Jammu, India</ce:textfn><sa:affiliation><sa:organization>Division of Veterinary Pathology</sa:organization><sa:organization>Sher-e-Kashmir University of Agriculture Sciences and Technology of Jammu</sa:organization><sa:city>R. S. Pura</sa:city><sa:state>Jammu</sa:state><sa:country>India</sa:country></sa:affiliation><ce:source-text id="staff0002">bDivision of Veterinary Pathology, Sher-e-Kashmir University of Agriculture Sciences and Technology of Jammu, R. S. Pura, Jammu, India</ce:source-text></ce:affiliation><ce:affiliation id="aff0003" affiliation-id="S2667031322000045-57024092c93063222f4b370cb32d0b90"><ce:label>c</ce:label><ce:textfn id="cetextfn0003">National Institute of Unani Medicine, Bangalore, Ministry of AYUSH, Govt. of India, India</ce:textfn><sa:affiliation><sa:organization>National Institute of Unani Medicine, Bangalore, Ministry of AYUSH, Govt. of India</sa:organization><sa:country>India</sa:country></sa:affiliation><ce:source-text id="staff0003">cNational Institute of Unani Medicine, Bangalore, Ministry of AYUSH, Govt. of India, India</ce:source-text></ce:affiliation><ce:correspondence id="cor0001"><ce:label>&#x204e;</ce:label><ce:text id="cetext0001">Corresponding author at: Regional Research Institute of Unani Medicine, University of Kashmir Naseem bagh campus, Habak, Srinagar, Jammu &amp; Kashmir, 190006 India, ORCID Id: .</ce:text><sa:affiliation><sa:organization>Regional Research Institute of Unani Medicine, University of Kashmir Naseem bagh campus</sa:organization><sa:city>Habak, Srinagar</sa:city><sa:state>Jammu &amp; Kashmir</sa:state><sa:postal-code>190006</sa:postal-code><sa:country>India</sa:country></sa:affiliation></ce:correspondence></ce:author-group><ce:date-received day="16" month="11" year="2021"/><ce:date-revised day="7" month="1" year="2022"/><ce:date-accepted day="8" month="1" year="2022"/><ce:abstract id="abs0001" view="all" class="author"><ce:section-title id="cesectitle0001">Abstract</ce:section-title><ce:abstract-sec id="abss0001" role="background" view="all"><ce:section-title id="cesectitle0002">Background</ce:section-title><ce:simple-para id="spara026" view="all">Presently, Diabetes mellitus (DM) is categorized as an epidemic disease due to its high prevalence of mortality rate and morbidity, and is also considered as the main threat to the global population. Synthetic drugs used alone for the treatment of DM cause serious adverse effects and insufficiently minimize diabetic complications. Meanwhile, the use of herbal drugs as standalone or along with synthetic drugs is quite common. Hence, the present study was carried out to evaluate the antidiabetic effects of <ce:italic>Saf&#x016b;f-i-Dhay&#x0101;b&#x012b;tus</ce:italic> as standalone and along with glibenclamide in streptozotocin-induced diabetic rats.</ce:simple-para></ce:abstract-sec><ce:abstract-sec id="abss0002" role="materials-methods" view="all"><ce:section-title id="cesectitle0003">Methods</ce:section-title><ce:simple-para id="spara027" view="all">In this study, a total of 30 albino Wistar rats of 150&#x2013;200&#160;g b. w. were randomly divided into 5 groups of 6 animals each. Diabetes was induced in all groups except in group I by administering a single dose of streptozotocin (STZ) at 55&#160;mg/ kg b. w. Group I served as plain control while group II as disease control. Group III was treated with glibenclamide at 0.6&#160;mg/ kg. b. w. and served as standard control while group IV received <ce:italic>Saf&#x016b;f-i-Dhay&#x0101;b&#x012b;tus</ce:italic> at 500&#160;mg/ kg b. w. and served as test group A. Group V administered <ce:italic>Saf&#x016b;f-i-Dhay&#x0101;b&#x012b;tus</ce:italic> at 500&#160;mg/ kg b. w. along with glibenclamide at 0.6&#160;mg/ kg b. w. for 21 days. The FBS of rats above 250&#160;mg/ dl was considered as diabetic, tested after induction of DM. The biochemical parameters such as FBS, ALP, TBR, SGOT, SGPT, blood urea and serum creatinine, total cholesterol and triglyceride; and histopathological examination of the liver and kidney specimens were carried out at the end of the study.</ce:simple-para></ce:abstract-sec><ce:abstract-sec id="abss0003" role="results" view="all"><ce:section-title id="cesectitle0004">Results</ce:section-title><ce:simple-para id="spara028" view="all">The FBG, ALP, SGPT levels in test group B were reduced significantly as compared to that of standard control, and test group A. The SGOT, TBR and b. urea levels in test groups A &amp; B were significantly reduced as compared to that of standard control. The s. creatinine level in test groups A &amp; B, and standard control was significantly reduced as compared to that of disease control. The total cholesterol level in test groups A &amp; B was promisingly decreased as compared to the standard control. Histopathological studies of the liver and kidney specimens of the rats belonging to test groups A &amp; B reduced hepato-nephrotoxicities in diabetic rats.</ce:simple-para></ce:abstract-sec><ce:abstract-sec id="abss0004" role="conclusion" view="all"><ce:section-title id="cesectitle0005">Conclusions</ce:section-title><ce:simple-para id="spara029" view="all">The present study revealed that <ce:italic>Saf&#x016b;f-i-Dhay&#x0101;b&#x012b;tus</ce:italic> as standalone and in combination with glibenclamide possesses significant hypoglycaemic, hepatoprotective, nephroprotective and hypocholesterolemic effects in STZ-induced diabetic rats.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:abstract id="abs0002" class="graphical" view="all"><ce:section-title id="cesectitle0006">Graphical abstract</ce:section-title><ce:abstract-sec id="abss0006" view="all"><ce:simple-para id="spara030" view="all"> [Display omitted] </ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords id="keys0001" view="all" class="keyword"><ce:section-title id="cesectitle0007">Keywords</ce:section-title><ce:keyword id="key0001"><ce:text id="cetext0002">Diabetes mellitus</ce:text></ce:keyword><ce:keyword id="key0002"><ce:text id="cetext0003">Saf&#x016b;f-i-Dhay&#x0101;b&#x012b;tus</ce:text></ce:keyword><ce:keyword id="key0003"><ce:text id="cetext0004">Antidiabetic</ce:text></ce:keyword><ce:keyword id="key0004"><ce:text id="cetext0005">Adjuvant therapy</ce:text></ce:keyword><ce:keyword id="key0005"><ce:text id="cetext0006">Glibenclamide</ce:text></ce:keyword><ce:keyword id="key0006"><ce:text id="cetext0007">Unani medicine</ce:text></ce:keyword></ce:keywords></ja:head></ja:article></doc:document>
